MX2023001312A - Inhibidores de quinasa y usos de los mismos. - Google Patents

Inhibidores de quinasa y usos de los mismos.

Info

Publication number
MX2023001312A
MX2023001312A MX2023001312A MX2023001312A MX2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A
Authority
MX
Mexico
Prior art keywords
compounds
methods
kinase inhibitors
compositions
kinase
Prior art date
Application number
MX2023001312A
Other languages
English (en)
Spanish (es)
Inventor
Chen Chen
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of MX2023001312A publication Critical patent/MX2023001312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023001312A 2020-08-07 2021-08-06 Inhibidores de quinasa y usos de los mismos. MX2023001312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2023001312A true MX2023001312A (es) 2023-04-12

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001312A MX2023001312A (es) 2020-08-07 2021-08-06 Inhibidores de quinasa y usos de los mismos.

Country Status (10)

Country Link
US (1) US20230303570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192582A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538521A (cg-RX-API-DMAC7.html)
KR (1) KR20230112605A (cg-RX-API-DMAC7.html)
CN (1) CN116710453A (cg-RX-API-DMAC7.html)
AU (1) AU2021321536A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002248A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179671A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001312A (cg-RX-API-DMAC7.html)
WO (1) WO2022032071A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120129682A (zh) * 2022-08-25 2025-06-10 英莱汶公司 用于抑制raf激酶的萘啶化合物
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
CN122555710A (zh) * 2024-01-15 2026-08-11 上海瑛派药业有限公司 Wee1抑制剂的晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2310657C2 (ru) * 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
CN109789143A (zh) * 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
BR112023002248A2 (pt) 2023-03-07
EP4192582A1 (en) 2023-06-14
AU2021321536A1 (en) 2023-03-09
KR20230112605A (ko) 2023-07-27
CA3179671A1 (en) 2022-02-10
JP2023538521A (ja) 2023-09-08
CN116710453A (zh) 2023-09-05
US20230303570A1 (en) 2023-09-28
WO2022032071A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
GEP20247679B (en) Bicyclic heterocycles as fgfr inhibitors
MX2022002271A (es) Compuestos de piridopirimidinonilo sustituidos utiles como activadores de celulas t.
BR112023002248A2 (pt) Inibidores de quinase e usos dos mesmos
PH12017500146B1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CU20150078A7 (es) Derivados de cicloalquilo pirrolo [2, 3-d]pirimidina -4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
EA201391528A1 (ru) Ингибиторы тирозинкиназы
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
MX2016000261A (es) Derivados de pirimidina como inhibidores de cinasa.
NZ718728A (en) Compound inhibiting activities of btk and/or jak3 kinases
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EA201591906A1 (ru) Производные мочевины, полезные в качестве ингибиторов киназы
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
JOP20170108A1 (ar) مثبطات معزز نظير zeste 2
JOP20240266A1 (ar) مركبات تريازولو ثلاثية الحلقة كمثبطات dgk
MX2023003996A (es) Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2023003995A (es) Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
MX2023006434A (es) Inhibidores de quinasa y usos de los mismos.
CO2019002171A2 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.
MX2025013034A (es) Inhibidores de egfr para el tratamiento de enfermedades
EA201792676A1 (ru) Ингибиторы jak1